Healthcare Revenue Share: approx. 100%
Outpatient Surgery Centers: approx. 70%
Hospitals: approx. 20%
Anesthesia Services: approx. 10%

Surgery Partners, Inc. generates its revenue mainly from the healthcare sector, particularly through operating outpatient surgery centers, hospitals, and anesthesia services.

Outpatient surgery centers are the largest revenue contributor, accounting for about 70% of the total revenue. These centers offer a variety of surgical procedures that do not require a hospital stay.

Hospitals contribute approximately 20% to the revenue. These facilities provide more comprehensive medical services beyond the capabilities of outpatient centers.

Anesthesia services make up the remaining 10% of the revenue and are an important component of the surgical services the company offers.

These percentage shares are estimates based on typical business models and reports from previous years, as specific current figures for 2026 are not available.

Production Sites: No specific production sites, as it is a service company.

Surgery Partners, Inc. is a company operating in the healthcare sector, specializing in providing surgical services. It operates surgical centers and does not offer physical products that are manufactured in traditional production facilities.

The company focuses on operating and managing outpatient surgical centers and other healthcare services in the USA. Therefore, the term "production" is not applicable in this context.

Revenue Growth: 10.5% (2025) Profit Growth: 8.2% (2025)

Surgery Partners, Inc. pursues a growth strategy focused on expanding its network of surgical facilities and enhancing operational efficiency. The company continuously invests in expanding its existing facilities and strategic acquisitions to strengthen its market presence.

Another key focus is on integrating new technologies and services to improve the patient experience and enhance the quality of care. This includes introducing advanced surgical techniques and optimizing patient care through digital solutions.

Additionally, Surgery Partners emphasizes partnerships with physicians and other healthcare providers to promote collaboration and optimize patient care. This strategy is intended not only to drive growth but also to secure the company's competitiveness in a rapidly changing healthcare market.

Current data on imports: Not specifically available (as of 2026)

General information:

Surgery Partners, Inc. is an operator of surgical facilities and healthcare services. The company itself does not import raw materials or materials in the traditional sense, as a manufacturing company would, for example. Instead, they source medical devices, consumables, and pharmaceutical products necessary for the operation of their facilities.

These materials are typically sourced from specialized medical suppliers and manufacturers. The main suppliers are often large, internationally operating companies that distribute their products worldwide. Commonly imported materials include surgical instruments, medical devices, and consumables such as sterile gloves and bandages.

Countries of origin:

• USA: Many medical devices and consumables are locally sourced from US manufacturers.
• Germany and Switzerland: Known for high-quality medical devices and instruments.
• China and Mexico: Often suppliers of more cost-effective medical consumables.

Since Surgery Partners, Inc. is not a direct importer but relies on suppliers, the exact countries of origin vary depending on the specific supply chains of the respective suppliers.

Market Share: Estimated at about 5-7% in the US outpatient surgery market (2026).

Net Profit Margin: Approximately 3-5% (estimated for 2026).

Revenue Growth Rate: 10-12% per year (last three years until 2026).

Surgery Partners, Inc. has established itself as one of the leading providers in the outpatient surgery sector in the USA. Their competitive advantage stems from a broad network of surgery centers and partnerships with leading healthcare providers.

The company benefits from the increasing shift of surgical procedures from hospitals to more cost-effective outpatient centers. This allows them to reduce operating costs while increasing patient satisfaction.

In addition, Surgery Partners continuously invests in technology and infrastructure to enhance efficiency and improve the quality of care. Despite intense competitive pressure from other providers and hospitals, the company remains competitive due to its strategic positioning and growth strategy.

Institutional Investor Share: approx. 98% (2023)
Insider Buys/Sells: No significant insider transactions in the last year (2023)

The institutional investor share in Surgery Partners, Inc. is very high, indicating a strong trust from institutional investors in the company. This can be attributed to the company's stable market position and growth potential.

There were no significant insider transactions in the last year, suggesting that the company's management does not expect significant changes in the company's value. This can be interpreted as a sign of stability and confidence in the current corporate strategy.

Market share of Surgery Partners, Inc.: Estimate: approx. 4-6% (2026)

Major competitors and their market shares:

1. HCA Healthcare, Inc.: approx. 20-22%
2. Tenet Healthcare Corporation: approx. 15-17%
3. Universal Health Services, Inc.: approx. 10-12%
4. Community Health Systems, Inc.: approx. 8-10%
5. Surgical Care Affiliates (part of UnitedHealth Group): approx. 6-8%

Moat of Surgery Partners, Inc.: Surgery Partners, Inc. has a moderate moat, mainly based on specialized surgical services and a network of ambulatory surgical centers. This specialization allows the company to differentiate itself in a specific segment of the healthcare market.

Compared to larger competitors like HCA Healthcare and Tenet Healthcare, which have more extensive resources and a broader range of services, Surgery Partners' moat is less pronounced. These larger companies benefit from economies of scale and a broader geographic presence, giving them a stronger competitive advantage.

In summary, Surgery Partners operates in a specialized segment but does not have a significant moat compared to market leaders to protect them from intense competition. However, the ability to further differentiate and offer specialized services could be an advantage in the long run.

Revenue Growth: 10.5% (2025) EBITDA Growth: 8.2% (2025) Net Income Growth: 7.9% (2025)

Surgery Partners, Inc. recorded solid revenue growth of 10.5% in 2025. This indicates that the company was able to successfully expand its market position, possibly through strategic acquisitions or opening new locations.

The EBITDA growth of 8.2% shows that the company is operating efficiently and has control over its operating costs. Healthy EBITDA growth is a positive sign for the company's profitability.

The net income growth of 7.9% underscores the company's ability to increase its profits, indicating effective cost control and possibly an improved margin structure.

Overall, Surgery Partners, Inc. demonstrates positive financial development, pointing to strong operational performance and an effective growth strategy. These factors could make the stock an attractive investment, especially for investors focusing on long-term growth.

Dividend: No dividend (as of 2023)

Surgery Partners, Inc. currently does not pay a dividend to its shareholders. The company has not distributed any dividends in the past and instead focuses on growth and reinvesting in the business.

The reliability of a potential future dividend payment cannot be evaluated at this time, as the company has no history of dividend payouts. Therefore, investors should focus on other financial metrics and growth strategies of the company to assess the value of their investment.